MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases

British Journal of Cancer

Volumn 110, Issue 12, 2014, Pages 2874-2880

  Nagy, E ^a   Gajjar, K B ^b   Patel, I I ^c   Taylor, S ^d   Martin Hirsch, P L ^b,e   Stringfellow, H F ^e   Martin, F L ^b   Phillips, D H ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b LANCASTER UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^e ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

Endometrial cancer; Epigenetics; Hypermethylation; K RAS; PTEN; Tamoxifen; TP53

Indexed keywords

AGED; BASE SEQUENCE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; EPIGENESIS, GENETIC; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SEQUENCE ANALYSIS, DNA; TAMOXIFEN; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84902546640     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.263     Document Type: Article

References (47)

1. Ali IU, Schriml LM, Dean M (1999) Mutational spectra of PTEN/MMAC1 gene: A tumor suppressor with lipid phosphatase activity. J Natl Cancer Inst 91: 1922-1932
2. Bansal N, Yendluri V, Wenham RM (2009) The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 16: 8-13
3. Biron-Shental T, Tepper R, Fishman A, Shapira J, Cohen I (2003) Recurrent endometrial polyps in postmenopausal breast cancer patients on tamoxifen. Gynecol Oncol 90: 382-386. (Pubitemid 36952031
4. Brandes JC, Carraway H, Herman JG (2007) Optimal primer design using the novel primer design program: MSPprimer provides accurate methylation analysis of the ATM promoter. Oncogene 26: 6229-6237. (Pubitemid 47414370
5. Brink M, De Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, De Bruine AP, Goldbohm RA, van den Brandt PA (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 24: 703-710. (Pubitemid 36592405
6. Chen G, Yin S, Maiti S, Shao X (2002) 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16: 279-285
7. Cheng ZD, Hu SL, Sun YB, Xu WP, Shen G, Kong XY (2010) Promoter methylation of CHFR gene in gastric carcinoma tissues detected using two methods. Chin J Cancer 29: 163-166
8. Chetrite GS, Cortes-Prieto J, Philippe JC, Wright F, Pasqualini JR (2000) Comparison of estrogen concentrations, estrone sulfatase and aromatase activities in normal, and in cancerous, human breast tissues. J Steroid Biochem Mol Biol 72: 23-27. (Pubitemid 30145713
9. Cohen Y, Shalmon B, Korach J, Barshack I, Fridman E, Rechavi G (2010) AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol Oncol 116: 88-91
10. Davies R, Gant TW, Smith LL, Styles JA (1999) Tamoxifen induces G:C-4T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 50-CpG-30 dinucleotide sequences as found in the lacI transgene. Carcinogenesis 20: 1351-1356. (Pubitemid 29341460
11. Davis W, Hewer A, Rajkowski KM, Meinl W, Glatt H, Phillips DH (2000) Sex differences in the activation of tamoxifen to DNA binding species in rat liver in vivo and in rat hepatocytes in vitro: Role of sulfotransferase induction. Cancer Res 60: 2887-2891. (Pubitemid 30395811
12. Esteller M, Hamilton SR, Burger PC, Baylin SB, Herman JG (1999) Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59: 793-797. (Pubitemid 29086728
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90: 1371-1388. (Pubitemid 28439961
14. Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, Riva C (2006) The high frequency of De novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 12: 3329-3336
15. Hachisuga T, Miyakawa T, Tsujioka H, Horiuchi S, Emoto M, Kawarabayashi T (2003) K-ras mutation in tamoxifen-related endometrial polyps. Cancer 98: 1890-1897. (Pubitemid 37310231
16. Hachisuga T, Tsujioka H, Horiuchi S, Udou T, Emoto M, Kawarabayashi T (2005) K-ras mutation in the endometrium of tamoxifen-Treated breast cancer patients, with a comparison of tamoxifen and toremifene. Br J Cancer 92: 1098-1103. (Pubitemid 40546675
17. Han J, Hankinson SE, De Vivo I (2006) Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis 27: 2281-2285. (Pubitemid 44644817
18. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826. (Pubitemid 26296693
19. Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143: 545-554. (Pubitemid 24058210
20. Jacinto FV, Esteller M (2007) MGMT hypermethylation: A prognostic foe, a predictive friend. DNA Repair (Amst) 6: 1155-1160. (Pubitemid 47058396
21. Janiec-Jankowska A, Konopka B, Goluda C, Najmola U (2010) TP53 mutations in endometrial cancers: Relation to PTEN gene defects. Int J Gynecol Cancer 20: 196-202
22. Kim SY, Suzuki N, Laxmi YR, Shibutani S (2004) Genotoxic mechanism of tamoxifen in developing endometrial cancer. Drug Metab Rev 36: 199-218. (Pubitemid 38802486
23. Koul A, Willen R, Bendahl PO, Nilbert M, Borg A (2002) Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 94: 2369-2379. (Pubitemid 34457118
24. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: Evidence of distinct molecular genetic pathways. Cancer 88: 814-824
25. Liu FS (2007) Molecular carcinogenesis of endometrial cancer. Taiwan J Obstet Gynecol 46: 26-32
26. Magriples U, Naftolin F, Schwartz PE, Carcangiu ML (1993) High-grade endometrial carcinoma in tamoxifen-Treated breast cancer patients. J Clin Oncol 11: 485-490. (Pubitemid 23071046
27. Malkin D, Jolly KW, Barbier N, Look AT, Friend SH, Gebhardt MC, Andersen TI, Borresen AL, Li FP, Garber J, Strong LC (1992) Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 326: 1309-1315
28. Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N (2008) Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis. Int J Cancer 122: 2429-2436. (Pubitemid 351590474
29. Phillips DH (2001) Understanding the genotoxicity of tamoxifen?. Carcinogenesis 22: 839-849
30. Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH (2005) Molecular genetic characterization of tamoxifen-Associated endometrial cancer. Gynecol Oncol 96: 25-31. (Pubitemid 39612413
31. Rimel BJ, Huettner P, Powell MA, Mutch DG, Goodfellow PJ (2009) Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol 112: 224-228
32. Shang Y, Hu X, DiRenzo J, Lazar MA, Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103: 843-852
33. Shen L, Kondo Y, Rosner GL, Xiao L, Hernandez NS, Vilaythong J, Houlihan PS, Krouse RS, Prasad AR, Einspahr JG, Buckmeier J, Alberts DS, Hamilton SR, Issa JP (2005) MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 97: 1330-1338. (Pubitemid 41487800
34. Singh MN, Stringfellow HF, Paraskevaidis E, Martin-Hirsch PL, Martin FL (2007) Tamoxifen: Important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 33: 91-100. (Pubitemid 46323395
35. Singh MN, Stringfellow HF, Walsh MJ, Ashton KM, Paraskevaidis E, Abdo KR, Martin-Hirsch PL, Phillips DH, Martin FL (2008) Quantifiable mRNA transcripts for tamoxifen-metabolising enzymes in human endometrium. Toxicology 249: 85-90
36. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356-362. (Pubitemid 27147102
37. Teo AK, Oh HK, Ali RB, Li BF (2001) The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. Mol Cell Biol 21: 7105-7114. (Pubitemid 32911269
38. Toguchida J, Yamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Ralph R, Weichselbaum RR, Yandell DW (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 326: 1301-1308
39. Turbiner J, Moreno-Bueno G, Dahiya S, Sanchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J (2008) Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Mod Pathol 21: 925-936
40. Utsunomiya H, Ito K, Suzuki T, Kitamura T, Kaneko C, Nakata T, Niikura H, Okamura K, Yaegashi N, Sasano H (2004) Steroid sulfatase and estrogen sulfotransferase in human endometrial carcinoma. Clin Cancer Res 10: 5850-5856. (Pubitemid 39180965
41. van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW, van Tinteren H, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, Otter R, Schouten LJ, Damhuis RAM, Benraadtc J, Bontenbal M (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343: 448-452. (Pubitemid 24059587
42. Wallen M, Tomas E, Visakorpi T, Holli K, Maenpaa J (2005) Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene. Cancer Chemother Pharmacol 55: 343-346. (Pubitemid 40379257
43. Williams-Brown MY, Salih SM, Xu X, Veenstra TD, Saeed M, Theiler SK, Diaz-Arrastia CR, Salama SA (2011) The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk. J Steroid Biochem Mol Biol 126: 78-86
44. Wu CM, Tang R, Wang JY, Changchien CR, Hsieh LL (2005) Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. Cancer Genet Cytogenet 158: 55-60. (Pubitemid 40354325
45. Xiong Z, Laird PW (1997) COBRA: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534. (Pubitemid 27303718
46. Yamamoto K., Yoshida R, Ogata T (2007) KRAS Analysis in 34 Noonan Syndrome Patients without PTPN11 Mutation. Clinical Pediatric Endocrinology 16: 99-101. (Pubitemid 350255381
47. Zhang F, Fan PW, Liu X, Shen L, van Breeman RB, Bolton JL (2000) Synthesis and reactivity of a potential carcinogenic metabolite of tamoxifen: 3,4-dihydroxytamoxifen-o-quinone. Chem Res Toxicol 13: 53-62. (Pubitemid 30055959.